AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02180828
Drug: Clotrimazole vaginal tablet
RxNorm normalized name: clotrimazole Vaginal Cream
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Trial: NCT02180828
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 doses of 150 mg oral Fluconazole (at day1 and day4)
Trial: NCT03376516
Drug: Wilate
RxNorm normalized name: Wilate
DrugBank: Von Willebrand factor human (DB13133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: von Willebrand factor / Factor VIII (plasma derived)
Trial: NCT01941602
Drug: prophylactic enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed
Trial: NCT01370876
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.
Trial: NCT01047189
Drug: clindamycin phosphate 1.2% and tretinoin 0.025%
RxNorm normalized name: clindamycin phosphate 12 mg in 1 g / tretinoin 0.25 mg in 1 g TOPICAL GEL [Clindamycin Phosphate 1.2% and Tretinoin 0.025%]
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: applied once daily for 12 weeks
Trial: NCT00706147
Drug: Arimoclomol
RxNorm normalized name: arimoclomol
DrugBank: Arimoclomol (DB05025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Arimoclomol capsules given three times per day
Trial: NCT01370187
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast 4mg daily for 2 months
Trial: NCT00284180
Drug: Vinflunine
RxNorm normalized name: vinflunine
DrugBank: Vinflunine (DB11641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel second generation vinca alkaloid
Trial: NCT00284180
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-HER2 monoclonal antibody
Trial: NCT01544673
Drug: linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg oral tablet twice daily for 4.5 days
Trial: NCT01905540
Drug: SSP-004184AQ
RxNorm normalized name: Cercidium floridum ssp. floridum pollen
DrugBank: Parkinsonia florida pollen (DB11006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium salt
Trial: NCT01905540
Drug: SSP-004184SS
RxNorm normalized name: Cercidium floridum ssp. floridum pollen
DrugBank: Parkinsonia florida pollen (DB11006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium salt
Trial: NCT01727934
Drug: Miravirsen sodium
RxNorm normalized name: Miravirsen
DrugBank: Miravirsen (DB12851)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT00216281
Drug: Clozapine augmented with atomoxetine up to 40 mg or placebo
RxNorm normalized name: atomoxetine 40 MG
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01451411
Drug: Conivaptan hydrochloride
RxNorm normalized name: Conivaptan Hydrochloride
DrugBank: Conivaptan (DB00872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT00020254
Drug: nilutamide
RxNorm normalized name: Nilutamide
DrugBank: Nilutamide (DB00665)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04034134
Drug: Jaktinib Hydrochloride Tablets
RxNorm normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg twice-daily (BID)
Trial: NCT04034134
Drug: Jaktinib Hydrochloride Tablets
RxNorm normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg quaque die (QD)
Trial: NCT04034134
Drug: Jaktinib Hydrochloride Tablets
RxNorm normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg quaque die (QD)
Trial: NCT00133627
Drug: Ketotifen
RxNorm normalized name: Ketotifen
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03147183
Drug: Thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
Trial: NCT00535418
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02099396
Drug: Docetaxel+lobaplatin
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02099396
Drug: Gemcitabine+lobaplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00198471
Drug: Vitrase
RxNorm normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02507154
Drug: Cetuximab + NK cells
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00577200
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam
Trial: NCT00577200
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.
Trial: NCT04513808
Drug: Propofol-based total intravenous anesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-based total intravenous anesthesia, titrated to clinical need.
Trial: NCT04513808
Drug: Sevoflurane intravenous anesthesia
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane intravenous anesthesia, titrated to clinical need.
Trial: NCT02865174
Drug: Topical tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular application of tranexamic acid 3g in 100 ml normal saline into knee joint after closure of the joint capsule
Trial: NCT02865174
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
Trial: NCT00973739
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.~Children/adolescents (\<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)~Adults (\>=18 years of age): 1,500 mg PO (6 tablets once daily)~Duration: Up to 12 months, depending on treatment response.
Trial: NCT00982488
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib was supplied as 20- and 50-mg tablets.
Trial: NCT00982488
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib was supplied as 100- and 400-mg tablets.
Trial: NCT01662908
Drug: edoxaban tosylate
RxNorm normalized name: Edoxaban Tosylate
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg once daily (QD) for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment
Trial: NCT01662908
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet for oral use; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; 90 days treatment.
Trial: NCT01759030
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
Trial: NCT00531232
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: Tablet,~Route of administration: Oral
Trial: NCT04941196
Drug: Anplag (Ticagrelor 90 mg)
RxNorm normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg Immediate Release tablet
Trial: NCT04941196
Drug: Brilinta (Ticagrelor 90 mg)
RxNorm normalized name: Brilinta
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg Immediate Release tablet
Trial: NCT03892161
Drug: Darunavir/ritonavir 800/100 mg tablet
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard dose DRV/r administered
Trial: NCT03796910
Drug: SPR720 for SAD
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered as a single dose.
Trial: NCT02762266
Drug: lipiodol
RxNorm normalized name: Lipiodol
DrugBank: Ethiodized oil (DB00965)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03978845
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using an ultrasound and a nerve stimulator, the phrenic nerve will be identified and low-dose lidocaine will be administered perineurally.
Trial: NCT03398330
Drug: Oxycodone Tamper Resistant
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally taking Oxycodone Tamper Resistant 40mg in fed state
Trial: NCT01143402
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01143402
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01143402
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00006021
Drug: arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03892161
Drug: Rifampicin 600mg QD tablet and DTG 50mg BD
RxNorm normalized name: rifampicin and isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin and DTG added
Trial: NCT02170064
Drug: BIA 2-093 (Eslicarbazepine acetate)
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
Trial: NCT00133133
Drug: ALGRX 4975
RxNorm normalized name: ALGRX 1207
DrugBank: ALGRX 1207 (DB06482)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04350684
Drug: Umifenovir
RxNorm normalized name: umifenovir
DrugBank: Umifenovir (DB13609)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Umifenovir in COVID-19 patients.
Trial: NCT04350684
Drug: Interferon-β 1a
RxNorm normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.
Trial: NCT04350684
Drug: Lopinavir / Ritonavir
RxNorm normalized name: lopinavir / ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Trial: NCT04350684
Drug: Single Dose of Hydroxychloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Trial: NCT02750514
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02750514
Drug: BMS-986205
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT02553629
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01302002
Drug: Metformin Pre-Surgery
RxNorm normalized name: ENSURE PRE-SURGERY LIQUID
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg tablet, taken twice a day for 3 weeks
Trial: NCT00872300
Drug: PHA-739358
RxNorm normalized name: PHA-767491
DrugBank: PHA-767491 (DB17043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
Trial: NCT01823289
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
Trial: NCT02022540
Drug: PAN-90806 Ophthalmic Solution
RxNorm normalized name: calcium carbonate
DrugBank: AN-9 (DB05103)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02022540
Drug: Lucentis
RxNorm normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02803203
Drug: osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02803203
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02797821
Drug: Asfotase alfa
RxNorm normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01812057
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 8 mg IV (as a one time dose)
Trial: NCT02348203
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02348203
Drug: Zileuton
RxNorm normalized name: Zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00811460
Drug: taspoglutide
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300micrograms/day sc for 2 days
Trial: NCT00811460
Drug: taspoglutide
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 micrograms/day sc for 2 days
Trial: NCT01249001
Drug: Oral Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will receive an oral suspension containing 125mg of Aprepitant
Trial: NCT01249001
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a 125 mg Aprepitant capsule
Trial: NCT02478489
Drug: Oral naltrexone (PO-NTX)
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral naltrexone
Trial: NCT02478489
Drug: Extended-release injectable naltrexone (XR-NTX)
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injectable naltrexone
Trial: NCT02455167
Drug: Simeprivir (SMV)
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Experimental Single arm study. All participants will get the same treatment.
Trial: NCT02455167
Drug: Sofosbuvir (SOF)
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental Single arm study. All participants will get the same treatment.
Trial: NCT02455167
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental Single arm study. All participants will get the same treatment.
Trial: NCT00147329
Drug: MM-093
RxNorm normalized name: MM-093
DrugBank: MM-093 (DB05512)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01880957
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01880957
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04062058
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 40-60mg/m2(according to patient's body surface area), orally twice daily every weekday concurrently with radiotherapy treatment
Trial: NCT04062058
Drug: SOX
RxNorm normalized name: Vasoxyl
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
Trial: NCT01378117
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 50-100mg po once daily
Trial: NCT01378117
Drug: glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: glargine once daily
Trial: NCT01378117
Drug: lispro
RxNorm normalized name: Lispro PRC
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: lispro before meals
Trial: NCT01126957
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine was given as a 0.5mg / Kg bolus.
Trial: NCT01126957
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol given to both arms to maintain sedation throughout procedure.
Trial: NCT00598507
Drug: ZK-EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were treated with 16 mg/m\^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.
Trial: NCT00157118
Drug: Protein C Concentrate (Human) Vapor Heated
RxNorm normalized name: PROTEIN C CONCENTRATE
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02375100
Drug: Bupivacaine %0.5 (hyperbaric)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02375100
Drug: Bupivacaine %0.25 (isobaric)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02375100
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be administered tramadol in postoperative period when their pain score exceeds 4 points (moderate pain)
Trial: NCT01361984
Drug: Nebulized arformoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arformoterol tartrate 15 µg/2ml (Brovana) nebulized via PARI-LC Plus® nebulizer with a mouthpiece, connected to a PRONEB® Ultra compressor. The nebulization time is \~9 minutes
Trial: NCT01361984
Drug: Salmeterol
RxNorm normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler
Trial: NCT03224039
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous push for one dose (active comparator)
Trial: NCT00820547
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant: 100 mg/m2 q3w, 4 cycles
Trial: NCT00820547
Drug: epirubicin hydrochloride
RxNorm normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
Trial: NCT01205503
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes
Trial: NCT01205503
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (used as a placebo) infused over the same time as mesna intervention
Trial: NCT01664754
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO